Tag: side effects
-
Syfovre Adverse Reaction Cases: Updated Number of Patients With Retinal Vasculitis, Timeline of Events
Additional Information from Apellis and the American Society of Retina Specialists About Ongoing Syfovre Safety Issues (Posted by Tom Lamb at Drug Injury Watch) UPDATE: From this February 28, 2024, Fierce Pharma news report, "Apellis cites…
-
Prolia – Hypocalcemia Side Effect Safety Signal May Draw Regulatory Action by FDA
"Risk of severe hypocalcemia" in Patients on Dialysis Receiving Osteoporosis Drug Prolia (denosumab) (Posted by Tom Lamb at Drug Injury Watch) The FDA is in the process of evaluating the osteoporosis drug Prolia (denosumab) to…
-
Valtrex Associated With Serious Skin Reaction DRESS Side Effect That Can Be Fatal, Says Health Canada
Canadian Product Monograph for Valtrex Now Warns About Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) (Posted by Tom Lamb at Drug Injury Watch) Valtrex (valacyclovir) is a long-established treatment for cold sores,…
-
Tepezza Hearing Loss: Cases of This Drug Side Effect Reviewed in Various Medical Journal Articles
This Treatment for Thyroid Eye Disease Was Approved by FDA in 2020, With Hearing Problems Reported Soon Thereafter (Posted by Tom Lamb at Drug Injury Watch) We recently wrote about Tepezza hearing loss cases in…
-
Byetta, Trulicity, Ozempic, and Adlyxin Linked to Gallbladder Disease Side Effects, Including Deaths
36 Cases of Acute Cholecystitis in Patients Taking Glucagon-like Peptide-1 (GLP-1) Receptor Agonists in FDA FAERS (Posted by Tom Lamb at Drug Injury Watch) A recent Research Letter written by three FDA employees with the…
-
How People Can Report Adverse Drug Reactions to the FDA, and What Happens to This Information Thereafter
From time to time we hear from people who want to know: (1) How they can report a serious prescription drug side effect, or adverse drug reaction, to the FDA; and, (2) What happens…
-
Xeljanz Safety Study Final Data Details the Increased Risks of Cancers and Major Adverse Cardiovascular Events
January 2022 Medical Journal Article Presents Full Set of Findings for the Xeljanz "ORAL Surveillance" Trial Which Started in 2014 (Posted by Tom Lamb at Drug Injury Watch) One year ago Pfizer released some preliminary…
-
Eli Lilly Attempts to Distance Olumiant From the Ominous JAK Inhibitors Drug Class Safety Issues Flagged by FDA
Xeljanz, Rinvoq, and Olumiant Are the Three Janus Kinase (JAK) Inhibitors Getting "Black-Box" Warnings Revisions, Soon (Posted by Tom Lamb at Drug Injury Watch) In September 2021 the FDA announced it was requiring revisions to…